7 biotech stocks with bounding share prices

Regeneus Ltd (RGS) was founded in Sydney in 2007 and went public in September 2013. The company uses adipose-derived cell therapies to treat inflammatory and orthopaedic problems in humans and animals. Adipose cells are basically fat storage containers. On 30 October the company announced the availability of something called HiQCell therapy in Melbourne for the treatment of sports-related muscular/skeletal disorders. HiQCell was developed by Regeneus and since 2011 has been used to successfully treat more than 800 arthritic joints in more than 350 people. To date, the company’s reach is limited to Australia. The company’s cell therapy treatments can be used in animals as well. On 14 November 2013 the US Department of Agriculture approved another of Regeneus’s therapies, a cancer vaccine for dogs made from the dogs own tissue. Share market participants were impressed.


Consider this. There are more than 40 million people in the United States alone suffering from some form of arthritis with about 26 million with osteoarthritis. Recent clinical studies indicate HiQCell therapy appears to have a positive impact on osteoarthritis. Watch this one.


http://www.thebull.com.au/premium/a/42153-7-biotech-stocks-with-bounding-share-prices.html


Love that last bit